ADIPOQ and hypertensive disorder: The impact of treatment with secukinumab and other biologics on other cardiometabolic risk factors, such as hypertension, adiponectin levels, dyslipidaemia and hyperuricemia, is also limited in patients with metabolic comorbidities [33,35].